Frontiers in nutritionAug 1, 2026

Changes in eating experience during GLP-1 receptor agonist treatment explained by food enjoyment and desire

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Aug 3, 2026

Abstract

Some patients receiving glucagon-like peptide-1 receptor agonists (GLP-1RAs) report altered eating experiences, such as food tasting different or being less enjoyable.

Altered eating experiences may relate to changes in how food is perceived rather than a uniform problem with taste.
Current evidence does not support a consistent primary impairment of basic taste function during GLP-1RA treatment.
Changes in food enjoyment appear to be linked to state-dependent revaluation of food and reduced motivation driven by rewards.
Responses to GLP-1RAs can vary widely among individuals, with some experiencing persistent appetite or weight regain.
This framework could help explain how GLP-1RAs affect food preferences and dietary behaviors.

Simplified

Eating experience is shaped not only by oral sensory input, but also by hedonic evaluation, interoceptive state, and cue-driven motivation. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for obesity treatment, offer a clinically relevant model for examining how these processes interact during appetite regulation. Some patients receiving GLP-1RAs report that food tastes different, is less enjoyable, or becomes less tempting, yet these experiences are often grouped together as "taste changes." This review argues that such reports should be interpreted through a sensory-liking-wanting framework rather than as evidence of a uniform gustatory disorder. We synthesise evidence from peripheral taste signalling, brainstem interoceptive integration, and central food reward pathways. Current evidence does not support a consistent primary impairment of basic gustatory function during GLP-1RA treatment. Instead, altered eating experience appears more consistent with state-dependent food revaluation and reduced reward-driven motivation. However, these responses are heterogeneous and may include limited response, persistent appetite, weight regain, or atypical behavioural phenotypes in some individuals. This framework may help clarify how incretin-based therapies influence food preference, dietary intake, nutritional behaviour, and treatment adherence.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

No commercial or financial ties reported.

PubMed

Changes in eating experience during GLP-1 receptor agonist treatment explained by food enjoyment and desire

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief